Abstract
Peptech is developing PMX-53, a complement C5a inhibitor for the potential treatment of inflammatory disorders, including rheumatoid arthritis and psoriasis. Phase Ib/IIa clinical trials have been completed for both indications.
| Original language | English |
|---|---|
| Journal | Current Opinion in Molecular Therapeutics |
| Volume | 8 |
| Issue number | 6 |
| Pages (from-to) | 529-538 |
| Number of pages | 10 |
| ISSN | 1464-8431 |
| Publication status | Published - 01.12.2006 |
